Adventrx Pharmaceuticals (ANX): Where Is ‘Fair Value’?

With 6 weeks to a U.S. Food & Drug Administration (FDA) decision on Adventrx Pharmaceuticals’ (ANX) Exelbine™, an enhanced formulation of the chemotherapy drug, vinorelbine, trading continues to be volatile. The reason?

Diverging opinion with a side of emotions at play.

Vista Capital Partners set a $7.50 price target on Adventrx shares in the latter part of June, two days after Rodman & Renshaw revised their target on the company upwards 355% to $16. Shares quickly leaped to a new 52-week high, on equally impressive volume. 

However, some investors are not as enthusiastic. Growing share volume has accompanied a growing short interest in Adventrx Pharmaceuticals’ shares. Investors betting on a decline in the company’s stock comprised 7.7% of the float at the end of June (NASDAQ.com). To top it off, TheStreet.com analyst Adam Feuerstein added:

Adventrx is overvalued (perhaps wildly so) on a fundamental basis. […]At the moment fundamentals don’t matter, but at some point, they will.

Feuerstein went on to explain that the addressable market for Adventrx Pharmaceuticals’ Exelbine™ is dismal, with U.S.sales of vinorelbine at $7 Million. Yet, this statement differs materially from a similar analysis in 2010, where Feuerstein wrote that the U.S. market for vinorelbine is worth $20 Million annually. In the unlikely event that the market for vinorelbine contracted 65% year-over-year (as the analyst’s research suggests), we took to Adventrx’s SEC filings for a precise answer:

Based on data from IMS Health, total vinorelbine sold in theU.S.in 2009 was approximately 9.4 million milligrams. We estimate that the current average sales price for generic, or multi-source, vinorelbine in theU.S.is between $1.40 and $1.50 per milligram

This puts U.S.sales of vinorelbine between $13.16 Million and $14.10 Million per annum – twice the number which Feuerstein quoted.

Pricing Strategy

Exelbine™, which would aim to replace branded and generic formulations of vinorelbine through its administering benefits, would offer Adventrx Pharmaceuticals pricing power over competitors if granted a unique Healthcare Common Procedure Coding System (HCPCS) product code. According to the company, a unique code would allow Exelbine™ to be quoted at its own price – regardless of the price of substitute products. Let’s put this into perspective with an example.

Microsoft controls the market for Office software. They are the sole supplier of Microsoft Office. While substitute products exist, they are not ‘identical’ to Microsoft’s Office Suite. This gives Microsoft leverage to price their product at a premium to substitutes. Adventrx’s plans for Exelbine fall along the same lines.

According to their annual report, Exelbine will be priced at $5-10 per milligram:

While we have not determined a price for Exelbine if it were approved by the FDA, we expect decision makers to value its unique formulation as compared to Navelbine and its generic equivalents, and we anticipate pricing Exelbine in theU.S.between $5 and $10 per milligram.

Valuation

Adam Feuerstein at TheStreet.com prepared a valuation for shares of Adventrx Pharmaceuticals assuming 50% market penetration for Exelbine by 2013 (that is, in two years). To be more conservative, suppose 33% penetration, and pricing at the low-end.

9,400,000 milligrams * 33% * $5/milligram = $15.67 Million in sales for fiscal 2013.

And, if Feuerstein wanted to know what those sales were worth to shareholders today, we would discount 15% and divide by a fully-diluted 35.67M shares (10Q), resulting in revenue per share of $0.38.  

At this stage, in place of a randomly assigned sales multiple (albeit, it is tempting), we’ll use the industry average price-to-sales ratio of 11.38 to measure ‘fair value’.

11.38 * $0.38/share = $4.32/share valuation.

Conclusion

Adventrx Pharmaceuticals will continue to trade in a volatile range at least until the FDA has rendered an opinion on Exelbine. Using a simple calculation, we showed that shares of this late-stage biotechnology firm are undervalued on the basis of a potential product approval and commercialization efforts. However, Exelbine’s FDA trial could also be the stepping stone for a multitude of products, including Adventrx’sANX-514, a novel, detergent-free reformulation of the chemotherapy drug docetaxel, andANX-188, a compound for the treatment of patients with sickle cell disease.

To support their efforts, cash and equivalents tallied $46.55 Million or $1.30/share, as of the most recent quarter.

Uplisting May Be Next For ImmunoCellular Therapeutics (OTCBB: IMUC)

 

It stands that as of Wednesday, shares of ImmunoCellular Therapeutics (IMUC.OB) have closed above the $2 threshold for 16 consecutive sessions – the most since marking a new 52-week high in March. ImmunoCellular Therapeutics CEO, Dr. Manish Singh, told us earlier this year that his firm would pursue listing their common stock on a national exchange to gain visibility, liquidity and suitability for a broader group of investors (more on this in a moment). Prior to our interview with Dr. Singh, we explained how a successful private placement already qualified ImmunoCellular Therapeutics for listing on the NYSE Amex under ‘standard 3′ (observe below).

 

In mid-May, ImmunoCellular Therapeutics filed its quarterly report, confirming our theory that the firm met listing requirements set by the NYSE Amex. Shareholders’ equity registered above the required $4 million; market capitalization rung north of the minimally permissible $50 million. Unfortunately, at the time, the stock price did not conform.

Rich Adamonis, a spokesperson for the NYSE, told us over the phone that the approval process for listing on the NYSE Amex typically takes from 3-6 weeks. Assuming ImmunoCellular Therapeutics submitted an application to the Amex sometime last month (when the share price broke above $2), the company could get the ‘go ahead’ as early as August, as all listing requirements are now met.

However, the listing itself isn’t a big deal – it’s everything that could come with it that is.

Funds, for instance, are often restricted from buying into companies that trade over-the-counter. Upon listing on the Amex, this restriction would be relieved, allowing greater investment to potentially flow towards ImmunoCellular Therapeutics. Additionally, the up-listing could bear inclusion into a number of small cap indices like the Wilshire U.S. Micro Cap Index, which is tracked by the Wilshire Micro Cap ETF (WMCR), Bridgeway Ultra-Small Company Market Fund (BRSIX), iShares Russell Microcap ETF (IWC), First Trust Dow Jones Select MicroCap ETF (FDM), and a host of others, including industry-specific indices like the Amex Biotechnology Index (ABT).

Inclusion in any index almost instantaneously registers new institutional holders in a company, as funds that mirror an index allocate shares of the newly included company to rebalance their portfolios. This takes from the float, which puts upwards pressure on the share price.

ImmunoCellular Therapeutics is roughly 32% owned by insiders; 11% belongs to funds. Dafna Capital Management LLC is one of two funds that recently started a position in ImmunoCellular Therapeutics. The fund’s chief investment officer was interviewed by Reuters and had the following to say on the topic of biotech companies that are focused on cancer being hot acquisition targets:

We have seen some very successful oncology drugs,” said Fariba Ghodsian, chief investment officer at hedge fund DAFNA Capital. “Novel drugs with novel targets are in demand.

According to NASDAQ.COM, Dafna Capital’s largest allocation is in Pharmacyclics Inc. (PCYC), a clinical-stage oncology firm focused on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Threshold Pharmaceuticals (THLD) and YM Biosciences (YMI) are the only other oncology holdings among the fund’s top 10. ImmunoCellular Therapeutics provides Dafna Capital exposure to an exciting and novel technology in immunotherapy, perhaps modeling Dendreon (DNDN) at a less ‘expensive share price’, to quote the Reuters columnist. One share of ImmunoCellular Therapeutics’ currently trades for about 1/1000th of one share of Dendreon. 

ImmunoCellular Therapeutics expects interim results from their Phase II study of ICT-107 in patients with glioblastoma multiforme (GBM) in the second half of 2012. Phase I studies returned fantastic results with 80% overall survival at the two-year mark compared with historical standard-of-care survival of just 26.5%; median progression free (PFS) survival of 16.9 months compared to the historic median PFS of 6.9 months. According to the same source, the company will also be filing an Investigational New Drug (IND) application with the FDA to move ICT-140, a vaccine for the treatment of ovarian cancer, into clinical studies early next year.

Bullish on Northwest Biotherapeutics (NWBO)? You Should Be.

Late last evening Northwest Biotherapeutics (NWBO) released news stating the company is expanding the number of clinical trial sites for their “ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer“.

This puts NWBO’s brain cancer drug on the fast-track to significant interim data and, eventually, commercialization (upon FDA approval).

This latest announcement follows very significant news from one week ago, which has since spurred the price onwards and upwards, quite notably.

NWBO is now working with Fraunhofer, the largest applied research foundation in Europe, to administer trials in Europe, as well as provide DCVax-Brain for compassionate care uses. What this means is sales in Q2 and yet another source of capital to finance operations.

See our coverage on the significance of those earlier news, including the partnership and approval for compassionate care uses in Europe, here.

Fast-forward to today. NWBO is in late-stage trials for a potential breakthrough product that will treat brain cancer. Dcvax-Brain has two significant advantages over current treatments: effectiveness (think what someone would give to live another year) and limited side-effects (think what patients treated with chemotherapy go through).

NWBO has just signed an agreement to sell this treatment in Europe under compassionate care uses, meaning revenues will soon start flowing in (beginning in this very quarter).

Yet, NWBO still trades for under $60M. To give you a benchmark for the potential inherit in this firm, consider Biovex, a private biotechnology firm that was in late-stage clinical trials for head & neck cancer when Amgen (AMGN) bought them out for $1 Billion. That buyout happened just earlier this year. And Biovex’s clinical data closely resembled the results that NWBO has been reporting in trials.

What Can You Expect? 

More of the same. Superior data from trials and continued expansion of the clinical study of DCvax-Brain in patients with brain cancer. Look for sales to reflect compassionate care uses of DCvax in Europe, in the second quarter. And don’t be surprised to see NWBO continuing to edge higher, incrementally. 

NWBO has the markings of a $100M company just based on where they are today. That, in itself, could mean a handsome return-on-investment (ROI). At another time we’ll look at how Dendreon’s (DNDN) prostate cancer drug made them a $6 Billion company. Their humble beginning is oddly familiar to NWBO, perhaps the firm next in line to introduce a novel brain cancer drug into the market.

Once bullish, famed contrarian Jim Grant sees trouble in rising markets. His advice: Hold cash

NEW YORK (AP) — Jim Grant quotes obscure dead economists at length. He pines for an earlier time of gas lights and top hats when the dollar was convertible to gold. He wears bowties.

Prolific author, gold bug, droll chronicler of Wall Street folly, Grant would be easy to dismiss as an entertaining but irrelevant throwback if he hadn’t been proven so right so often. Now, as small investors are putting more money into markets, the publisher of the biweekly Grant’s Interest Rate Observer is warning of new dangers. He says prices are too high for nearly every asset you can think of – stocks, junk bonds, Treasury bonds, British gilts, even Iowa corn fields.

With its wry observations about investor self-delusion, Grant’s newsletter ($910 for an annual subscription) has become a sort of bible among the bold and bearish alike. Though detractors say he’s far too negative, he’s been praised for some timely calls. In the 1980s, he warned of an overheated junk bond market before it collapsed. He foretold of the bursting of the tech bubble in the late 1990s, and revealed the false alchemy of Wall Street’s mortgage packaging business before housing crashed four years ago.

Occasionally, he’s gotten bullish at the right time, too. Amid the panicked selling of late 2008, Grant told readers to load up on investment grade bonds, junk bonds, even a few of those much-derided mortgage securities. Some picks have more than doubled since.

A graduate of Indiana University, Grant, 64, was a Navy gunner’s mate before starting his journalism career at the Baltimore Sun in 1972. He then joined the financial weekly Barron’s before starting Grant’s Interest Rate Observer in 1983. He’s also written seven books, mostly financial histories and profiles. His first book was on Bernard Baruch, the pre-WWI financier and advisor to presidents. His latest is a profile of Thomas Reed, an acerbic and witty Speaker of House over 100 years ago.

As stocks were falling last week, Grant visited The Associated Press in New York to talk about why it’s not just stock investors who should be worried. Below are excerpts, edited for clarity, from a wide-ranging conversation in which he lit into the Federal Reserve for our current troubles, warned of 10 percent inflation and waxed nostalgic for a time when Washington had the courage to let prices fall in crises rather than goose them up and prolong our agony.

Q: What’s your view of the stock market?

A: The Federal Reserve has unilaterally taken it upon itself to levitate asset prices. It is suppressing interest rates. When you’re not getting anything on your savings, you are inclined to go out and buy something, anything, to generate either income or the expectation of capital gains. So the things that we take as prices freely determined are in fact manipulated.

A few months ago, (Fed Chairman) Ben S. Bernanke, Ph.D., the former chairman of the Princeton economics department, stood before the cameras of CNBC and said that the Russell 2000 is making new highs. The Russell! He sounded like another stock jockey. He was taking credit for new highs in the small cap equities index. The Fed, as never before, or rarely before, is now the steward of this bull market. One wonders what it will do if stocks pull back significantly.

Q: Are stocks overvalued?

A: Some big multinationals left behind in the past ten years (like) Wal-Mart, Cisco Systems, Johnson & Johnson appear to be attractively priced. But generally speaking, things are rich.

Q: What would you have done in the financial crisis if you had been in Bernanke’s position?

A: Resign. I don’t know. I have great faith in the price mechanism, in the mechanics of markets. I think there should have been much less intervention and we should have let some chips fall, many chips fall.

Before the Great Depression, there was a great depression (lower case `g’) in 1920-21. Within 18 months, the GDP was down double digits and commodity prices collapsed. Harry Truman lost his haberdashery in Kansas City. It was very painful, but it ended. And the Fed, during that depression, actually raised its discount rate and the Treasury ran a surplus. The reason it ended was the so-called real balance effect – that is, prices came down and people with savings saw things that were cheap and they invested. That’s the fast and ugly approach.

The slow and ugly approach is to mitigate, temporize and forestall to give us time to work ourselves out of difficulties. That’s the current approach. I think it’s intended to be a more humane approach, but I wonder about its humanity. I mean these college kids get out of school and they’ve got nothing. It’s awful – 9 percent unemployment and going nowhere except sideways.

Q: But Bernanke has succeeded by some measures. Big companies are flush with cash, their profits are on track to hit a record this year and the riskiest among them are raising money at the lowest rates ever. Who could have imagined this during the depths of the financial crisis?

A: Let’s go back to the previous cycle of 2002-3. Cisco Systems was for 15 minutes the costliest company on the face of the earth, and digital technology was about to raise every human being out of poverty. OK, so that cycle ends – Bang! – with general disarray in the stock market. What do we do? Well, we press down interest rates and we give residential real estate a little helping hand. What’s not to like? Home ownership rates are rising. Stocks are up. Risky companies are issuing debt at levels never before imagined.

Who would have dreamt such an outcome was possible after the tech bust? And that ended noisily and here we are again and our monetary masters have devised new, even more audacious methods of stimulus. In three or four years we’ll look back and say, `Can you believe we fell for this again?’

Q: You’ve been warning about higher inflation for a while. How imminent is it?

A: I’ve been all wrong on this. I thought that this massive monetary stuff would generate the conventional kind of inflation that would be expressed in much higher CPI readings. Not so far. But all things are cyclical and the seemingly impossible is just around the corner. On September 30, 1981, the 30-year US Treasury bond traded at 14 7/8 percent and I remember some crank, some visionary, was talking about how interest rates were going to zero, you watch. Oh, yeah right. And so it came to pass.

It does seem improbable that the inflation rate would ever get beyond 3.5 percent, let alone knock on the door of 10 percent. But I’m here to tell you it’s going to 10 percent.

Q: Won’t policymakers come down hard if we get even 6 percent inflation and try to lower that?

A: Sometimes they can’t control things. We had 6 percent inflation before. Washington is full of well-intentioned people. Ben Bernanke keeps saying that what we really need is a little inflation. He says we’ll get 2 percent or a little bit more. You shouldn’t even think that, let alone say it out loud. That’s such bad luck to tempt fate by saying that you can calibrate things like that. You can’t do that.

Q: So with inflation ahead, are you buying gold at $1,480 an ounce?

A: I am not buying it now. I have bought it in the past. Gold is a very difficult investment because its value is indeterminate. It is the reciprocal of the world’s confidence in the likes of Ben Bernanke. I think the price will go higher.

Q: When did you first buy gold?

A: Well, my first misadventure with gold was standing in a queue in front of the Nicholas Deak currency and coin shop, which was on lower Broadway. And it might have been January of 1980 at the very peak but if not then, it was late 1979. I almost top ticked it. That was before I learned never to stand in line to buy an asset. You always want to go where nobody else is in line.

Q: Let’s talk about the dollar. Washington says it wants a strong dollar.

A: It’s disingenuous when (Treasury Secretary) Tim Geithner says he’s for a strong dollar. What he means to say is the economy stinks and we need even greater oomph from our exports and for that we would like a much lower dollar in a measured, managed kind of decline. That’s what he wants, and he wants it by November 2012.

Q: What’s wrong with a weak dollar? Caterpillar recently said it is nearly doubling its capital spending because the weak dollar allows it to sell more overseas. It plans to spend much of that on factories in the U.S., paying construction workers to build them and hiring people to work in them.

A: Well, that is the Caterpillar story. The whole manufacturing story in the U.S. is very sunny, and it’s in part due to the state of the dollar. But if (prosperity) were as easy as debasing one’s currency, think of all the countries that would be prosperous that are rather the opposite. Argentina would be booming. And Weimar Germany would not be a story of failure but of success.

If the world were to lose confidence in (the dollar) we would suddenly be in a much less advantageous financial position. The U.S. is uniquely privileged in that we alone may pay our bills in the currency that only we may lawfully print. That’s our prerogative as the reserve-currency country. But it has seduced us into a state of complacency. We never actually pay the rate of interest that we might be expected to pay – the real rate of interest – on Treasury debts.

It’s great for now that we’re paying 2.5 percent or whatever on our public debt. But wouldn’t it be better if there were an accurate price signal that was telling us that we’re borrowing too much?

Q: If investors lose their faith in the dollar, what would replace it?

A: I think there will be a gold standard again in your lifetime, if not mine. It’s the only answer to the question, if not the dollar, then what?

Q: Where should people put their money now?

A: The trouble with the present is that nothing is actually cheap. My big thought is that our crises are becoming ever closer in time. The recovery time from the Great Depression was 25 years. The stock market peaked in 1929. It got back there in 1954. We had a peak in 2000, crash, levitation, then the biggest debt crisis in anybody’s memory. The cycles are becoming compressed. The temptation to become invested at peaks of these shorter cycles is ever greater.

Perhaps one way to proceed is to hold cash at the opportunity cost of not much in Treasury bills. You make nothing, but you want to have this money when things are absolutely, not just relatively, cheap. This time of full or overvaluation shall pass. On recent form, it’ll pass in a thunderclap and there will be a panic and it’ll seem as if the world’s ending. And that’s when somebody who is nimble can get fully invested in a comfortable way.

It won’t feel comfortable, it will feel awful, but I think that’s the way to do it. I mean everything (you could invest in) is either uninteresting or rich, it seems to me.

Q: What about Treasury bonds?

A: I think it’s useful to imagine how things might look ten years hence. What will one’s children, heirs or successors think about a purchase today of ten-year Treasurys at 3.25 percent? They’ll look back and say, `What were they thinking?’ The (federal deficit) was running at 10 percent of GDP, the Fed had pressed its interest rates to zero, it had tripled the size of its balance sheet, and they bought bonds? Treasurys are hugely uninteresting, as is similar government debt the world over.

Q: Any last thoughts?

A: Because the Fed has coaxed or cajoled people into stocks, including many financial non-professionals, I think it has moral ownership of the market in a way that no recent Fed has had. Either the stock market owns the Fed, or vice versa but they are too intertwined now. If stocks pull back by 20 percent, how can Bernanke just sit there and say, `I want a bear market?’ I think he has some moral responsibility for the finances of the non-professionals who bought.

Q: Does this mean the Fed might announce QE 3, a third round of quantitative easing to lower rates and raise stock prices?

A: Yeah, it means QE 3 through QE N.

Written by BERNARD CONDON

Northwest Biotherapeutics (NWBO) Could See a Return to Higher Prices

Historically, Northwest Biotherapeutics (NWBO) has trended at or near its 50-day moving average (observe chart below).

Northwest Biotherapeutics chart

Deviation below the 50-day moving average (MA) has commonly resulted in a buying opportunity, as the price tends to adjust back upwards to the 50MA. Now, for the third time since 2007, Northwest Biotherapeutics shares have deviated significantly (~44%) below their historical price average.

Is there reason to believe the price may presently adjust back to the 50MA?

The scent of material news is looming. Recent SEC filings reveal the company has entered into arrangements with private investors to raise capital needed for funding clinical trials of the company’s immunotherapy drug, DCVax, in brain and prostate cancers. As capital shortfalls have plauged clinical development, a financing agreement would be significant enough to bolster shares back to the 50MA, and beyond.

Speculation aside, Northwest Biotherapeutics (NWBO) has returned meaningful data from clinical trials in Glioblastoma (brain) and prostate cancer, respectfully.

Under DCVax®-Brain, median survival of newly-diagnosed patients with glioblastoma, a common form of brain cancer, was 36.4 months, comparing favorably to the standard of care median of just 14.6 months. Treatment of brain cancer under the standard of care would include surgery, radiation therapy and Temodar, a compound distributed by Merck (MRK). Under this care, however, only 26% of patients live beyond two years; more than 69% have survived after being treated with DCVax.

Invariably, Northwest Biotherapeutics’ strides are aimed at a fairly unsatisfied market, where DCVax®-Brain has shown clinical significance (see figures, below).

Northwest Biotherapeutics DCVax

Northwest Biotherapeutics DCVax 

The end-goal then, perhaps, is a new and superior standard-of-care that includes Northwest Biotherapeutics’ DCVax®-Brain.

DCVax®-Prostate, FDA-cleared to undertake Phase III trials for prostate cancer, competes in a market familiar to Dendreon (DNDN) shareholders. The once small, now $5 Billion biotechnology company found fame in FDA-approved Provenge, which is used to treat prostate cancer. Like Provenge, DCVax®-Prostate is an immunotherapy that ”utilizes a patients own dendritic cells, and an antigen or target protein, to induce an immune response“. Without diving into too great detail on the similarities or dissimilarities, the schedule presented (below) speaks volumes about the data collected in earlier trials of DCVax®-Prostate.

Northwest Biotherapeutics survival data

Evidently, Northwest Biotherapeutics has a legitimate product candidate for the treatment of both prostate and brain cancer. Should the company strike a deal that will fund late-stage trials, investors may very well begin to wager on the success of this organization. Earlier this year, Amgen (AMGN) acquired privately-held Biovex, a biotechnology firm that was developing a vaccine for head & neck cancer. They were in stage III trials when the pharmaceutical giant took notice and offered $1 Billion to buy them out. Northwest Biotherapeutics’ DCvax has shown efficacy that even Biovex’s vaccine fell short of.

Coffee Holding Co. (NASDAQ: JVA) – Shrewdly Overvalued

This past Thursday, Coffee Holding Co., Inc. (NASDAQ: JVA) published results for its first operating quarter of 2011. For the period ended January 31st, net sales were up 20% compared to the same period in 2010. However, in the two trading sessions that ensued the financial report, shares rose 74% to the tune of shrewdly overvalued.

In the press release accompanying financial results for the most recent quarter, the company wrote:

“The increase in net income primarily reflects increased gross profit”.

True. If overhead costs remained stable, and sales grew, then the contributing factor would have to be gross profit. This piqued one inquirer’s interest in that it implied gross margins remained stable. But the company itself concluded in the very same press release that “commodity pressure” and “dramatically increased coffee prices” placed a burden on their business. This would imply shrinking margins.

“Our horizontal integrated business structure combined with our hedging policies helped us to significantly alleviate these higher costs as evidenced by our cost of sales only slightly increasing by 0.02 % during a time when the underlying commodity increased by over one dollar per pound as the fundamentals in the coffee market led to higher futures prices.”

This hedging policy, disclosed in their 10Q filing with the SEC, shows that speculation in the futures market led to a favorable gross margin. The slight 0.02% increase in the cost of sales was, therefore, attributable to a one-time gain on futures contracts. Here’s a detailed look at the disclosure.

 

For the three months ended January 31st, 2011 gains totaled $680,000 versus $135,000 in the comparable period of 2010 (see above schedule). That $545,000 contribution made up the difference in bottom line earnings from one period to the next.

Herein lie two key points.

The first is that an improved bottom line in the most recent quarter is not the result of growing or otherwise enhanced operations.

“The increase in net sales reflects higher sales prices compared to the first quarter of fiscal 2010[...]“

As input prices increased, the company was forced to increase the price at which it distributes its products. While the nominal numbers impressed investors, the 20% jump in net sales does not necessarily mean that quantity sold increased substantially. In fact, by the numbers, it’s difficult to point out any material change from last year.

Further, excluding the one-time gain from futures speculation, gross margins were depressed when compared with the same period in 2010. And income, adjusted for this event would contribute approximately the same earnings per share as in 2010. Therefore the ecstatic reaction in the stock’s market was unjustified.

The second point is that market prices fluctuate – everything from commodities to equities to currency. So to expect gains from futures contracts to rescue the company’s shrinking margins quarter after quarter is a dangerous assumption. Markets are uncontrollable, which exposes the company to potential losses on their derivative bets. In all likelihood, Coffee Holding Co.’s overvaluation was the result of investors assuming uncertain (but favorable) events without factoring in potential risks in this business.

If not the numbers, then what led to the surge in stock price and trading volume? Deja-vu – market speculators. So ask yourself, suppose other investors realize Coffee Holding Co. isn’t the growth story they sought out for. And suppose, next quarter, earnings came in flat, instead of improving over last year’s. Would that justify the stock price sliding back down to $4/share?

Beyond a reasonable doubt Coffee Holdings Co., Inc. is overvalued at its current market price.

Disclosure: I have no position in JVA at time of writing but may initiate a short position in the next 48 hours.

UK Classified Ads

You have to love British humour!  These are classified ads which were actually placed in a U.K newspaper:

FREE YORKSHIRE TERRIER.

8 years old.
Hateful little bastard.
Bites!

FREE PUPPIES.
1/2 Cocker Spaniel,
1/2 sneaky neighbour’s dog.

FREE PUPPIES.
Mother is a Kennel Club registered German Shepherd.
Father is a Super Dog, able to leap tall fences in a single bound.

COWS, CALVES: NEVER BRED.
Also 1 gay bull for sale.

JOINING NUDIST COLONY!
Must sell washer and dryer £100.

WEDDING DRESS FOR SALE .
Worn once by mistake.
Call Stephanie.

 

**** And the WINNER is an oldie but fantastic! ****

FOR SALE BY OWNER.
Complete set of Encyclopaedia Britannica, 45 volumes.
Excellent condition, £200 or best offer.
No longer needed, got married, wife knows everything.

ImmunoCellular Therapeutics (IMUC), Technically Speaking

This Afternoon, ImmunoCellular Therapeutics’ (IMUC) CEO, Manish Singh, Ph.D., is scheduled to present at the 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. The conference should attract institutional investment, as fund managers learn of the cancer therapeutics ImmunoCellular (IMUC) is developing. As noted in a written analysis, ImmunoCellular’s lead product candidate, ICT-107, returned stellar results from Phase 1 clinical trials in the treatment of brain tumors.

Above-average share volume has been seen for at least 8-consecutive trading sessions, coincidentally since we began coverage of ImmunoCellular Therapeutics (IMUC). During this period, the stock price has gained $0.50 or 28%, encroaching on a new 52-week high. While drivers such as clinical trial results, product and corporate developments remain fundamental, relative price movement will be the catalyst to market momentum for this small biotechnology firm.

As we explain in the following video, relative price movement is an analysis of the price at a specific point in time, better known as technical analysis. Using IMUC’s chart, we interpret the relative price at this point in time, the key technical drivers moving forward, and what the technical indicators are telling us. 

Regarding the company’s presentation at the 13th Annual BIO CEO & Investor Conference, a webcast of the event will be available at http://www.veracast.com/webcasts/bio/ceoinvestor2011/68111156.cfm


Please note that we have previously been compensated for voicing an independent investment opinion of ImmunoCellular Therapeutics, Ltd. The views expressed are purely our own and do not constitute a buy or sell recommendation. See our disclaimer for details.

Today In Small Biotech

There’s a lot going on in small cap biotech, even more so when you take into perspective the entire sector. What I’ve attempted to do is organize a brief overview of a few key biotechs making significant strides by way of price and volume. For the purposes of this report, the objective was to find companies with a capitalization under $500M, traded under $5/share, and seeing abnormal volume. The results of that screen were further narrowed down by looking at a key factor in low debt/equity. In fact, all of the companies listed (below) have hardly any debt to speak of and cash positions to justify variable levels of stability. The last criteria was for short interest to be at or below 5%. 
 
Thursday’s spotlight spent a considerable portion of time over at Rexahn Pharmaceuticals (RNN), whose shares closed at a new 7-month high on Monday. By the end of the session, investors valued the company 24% higher on the basis of last week’s $3.95 Million injection by Teva Pharmaceutical Industries (TEVA), who now owns 6.29% of the company, and the likelihood of something good coming out of ongoing Phase 2 clinical trials for three separate drugs.
 
ImmunoCellular Therapeutics (IMUC.OB) was also the beneficiary of a new 7-month high price after announcing their first patient had enrolled in Phase 2 clinical trials for ICT-107, a cancer vaccine targeting glioblastoma, late last week. They have a considerable portion of cash on hand relative to their burn rate and no debt. More information can be found in my earlier write-up on the company.
 
Repros Therapeutics (RPRX) was another recipient of abnormal share volume, which propelled its stock price higher on Monday. In January the company reported it had received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. More importantly, their offering of common stock and warrants is expected to close “on or about February 8th, 2011″, and the $11 Million they will raise “is expected to provide Repros funding into mid-2012″.
 
Zalicus’ (ZLCS) oncology research collaboration agreement with Novartis was extended to May 2012 in early January. The only other noteworthy event that I could find regarding this company without getting specific was a bio conference they are presenting at. Zalicus followed suit gaining 6.25% on Monday; volume topped the 3-month average roughly 37%.
 
Unlike its biotechnology counterparts, Orexigen Therapeutics (OREX) is still trading well below 52-week highs, but quickly moving higher after being discounted 70% last week. Shares bottomed at $2.5 and have already pierced the $4 mark just four sessions later. The FDA turned back their application for a weight-loss drug that would have essentially ‘made’ the company. Instead, Orexigen has some work ahead of itself before it can resubmit an application to the Food & Drug Administration and potentially reap approval.
 
Neoprobe (NEOP) held its own revealing the long wait for listing on the AMEX is no longer a wait at all – shares will begin trading on the NYSE Amex “on or about February 10, 2011″. As volume traded was twice that of the 3-month average, shares enjoyed a modest 3.37% rise. The up-listing announcement, however, came out after hours and should give shares a boost this coming session.

Disclosure: I’ve been compensated for writing an independent opinion regarding ImmunoCellular Therapeutics.

About the Internationalization of the Chinese Yuan

One of the fundamental characteristics of the global financial architecture is that the world’s second largest economy maintains a rigidly controlled currency. The concept of currency wars, as initially articulated last year, seemed to have been a criticism of the easy monetary policy of the Federal Reserve. But it is being appropriated and used as a criticism of the lack of flexibility of the Chinese yuan.

The reluctance of Chinese officials to allow its currency to be another shock absorber in the circuit of capital means that other liquid flexible or floating currencies have to shoulder a greater burden of the adjustment. Some, like a well respected analyst at a recent industry conference in New York, suggest that as long as Asian currencies remain under-valued, that the European currencies will remain over-valued, and by implication other currencies as well.

Given the tightly controlled yuan market, the extent of its use offshore is a development that is capturing the imagination of many observers and participants. Entities like the World Bank’s International Financial Corp, the Asian Development Bank, McDonald’s (MCD), Caterpillar (CAT) and some of the largest banks in the world have issued yuan denominated bonds in recent months. Billions of dollars in trade is being settled in yuan. The amount of yuan on deposit outside China is growing rapidly. Some observers suggest that this is the beginning of the Chinese yuan becoming a truly global currency and a rival to the privileged place of the U.S. dollar.

Hong Kong

There is both less and more than meets the eye in terms of the internationalization of the yuan. The internationalization of the yuan is less than it may seem because it has been largely confined to Hong Kong, a special administrative region of China. Yet at the same time, it reveals the savvy financial prowess of the Chinese government and is pregnant with vast potential. At the very least, China has found a way to profit from the speculative interest in the yuan; betting as it were, on its appreciation.

China has allowed an interbank market for the yuan to flourish in Hong Kong since last July. If there is a consensus among hedge funds and other speculators, it is that the yuan is going to appreciate in the short and long-term. On the other side are businesses, often Chinese companies owned or backed by the government, who want to borrow yuan to fund onshore operations. Owing to the strong demand for yuan denominated financial products, the cost of (yuan) capital is less than half of what it is onshore.

The yuan raised in Hong Kong is regarded by Chinese officials as a foreign currency (the common mnemonic is CNH to distinguish it from the onshore yuan CNY). The process by which CNH can be brought onshore—transformed into CNY—is not yet transparent. It has not been standardized as are the procedures for dollars, for which there is a clear channel and necessary steps. The yuan raised in Hong Kong is brought into China on a case-by-case basis.

It appears to be guided by Chinese officials to help achieve policy objectives. The location of the borrowing company’s mainland operation seems to be important as the provincial governments are ultimately behind the process. The sector the borrowing company operates in is also important. If it is for a sector that officials worry about overheating or excess investment, it is reportedly more difficult to get authorities to bring the funds onshore.

Domestic Offshore Market

The number of institutions in Hong Kong authorized to do yuan banking business has increased from around 65 at the start of 2010 to more than 100 by the end of the year. Yuan deposits in Hong Kong (CNH) was near 300 billion (~$43 billion) at the end of 2010, more than quadrupling over the course the year. To put that in perspective, the deposits in the mainland (CNY) are on the magnitude of 60 trillion. CNH accounts for roughly 4.5% of Hong Kong’s M2 money supply and about 10% of the foreign currency component of M2.

China has also been encouraging the use of the yuan to settle trades. In October 2010, the most recently available data suggests that trade worth some $10 billion was settled in yuan in October, doubling from the month before. Overall, imports plus exports were near $70 billion, but a more appropriate metric may be imports from the mainland. In that respect, more than half of Hong Kong’s imports from China were settled in yuan. Note, too, that nearly half of Hong Kong’s imports get re-exported.

Arbitrate opportunities have made the gap between the CNH and CNY nearly disappear. The mid-October 2010 CNH was as much as 2.6% richer than CNY. In recent days, the gap was 0.07%. The wide spread drew Chinese companies’ interest.

Consider a chip maker which was to build a new fabrication plant in the province of Fujian. It would need to import capital equipment. The supplier was unwilling to accept yuan as it is not convertible. The company could send yuan to its Hong Kong subsidiary which can swap it for dollars at the better offshore rate.

The Future of Two Currencies- One Country

The Hong Kong dollar has been pegged to the U.S. dollar since 1983. The peg has come under attack in the past, most notably during the 1997-98 Asian financial crises. Officials creatively defended the band and remain committed to it. Some observers suggest that over time, the yuan will supplement and then supplant the Hong Kong dollar.

Hong Kong banks are allowed to issue yuan raised in bond sales. Hong Kong depositors can increase yuan savings by converting up to a fixed amount of Hong Kong dollars a day to yuan. That cap is currently around $2500 a day. Hong Kong registered companies can convert foreign currencies into yuan in lieu of U.S. dollars. Indeed some recent pressure on the Hong Kong dollar, well above the floor permissible by the peg, may have been stemmed from moving into yuan.

Yet we should not believe for a moment that it is a free market. Chinese officials still retain control of the process; regulating the speed and quantity that CNH can become CNY. Hong Kong Monetary Authority maintains strong local control. It requires that banks document trades and discourages speculation.

The HKMA Chief Executive Norman Chan has outlined four conditions that would need to be met to peg the Hong Kong dollar to the Chinese yuan instead of the dollar:

  • China has an open capital account
  • China has a freely convertible currency
  • China has a mature financial system
  • China and Hong Kong economies are closely aligned

In late 2010, Chan said that none of the criteria had been met.

Evolving Market

China wants to control the pace and draw advantage from the seemingly insatiable demand for yuan exposure. Dim Sum bonds exploded on the scene in 2010. Thirty-three deals raised a cumulative sum of about CNY42.5 billion.

The pace picked up a bit in early 2011, but the bigger story may be synthetic yuan bonds. Investors buy the bonds with U.S. dollars and are paid back in yuan. In January, there have been more issues than all last year and they have raised five times more. Nearly four times more money was raised in January in synthetic yuan bonds than in the Dim Sum market. This market is dominated by Chinese property developers.

In mid-January, China announced that mainland fund managers could raise money in Hong Kong for investment in the domestic market, but 80% of the funds raised must be invested in the Chinese bonds market. Around the same time, China indicated it would allow its companies to make foreign acquisitions using yuan. Also starting in January, the Bank of China (BACHY.PK), the country’s fourth largest bank began offering yuan deposits at its U.S. branches.

These are still early days of the internationalization of the yuan and the Sino-ification of Hong Kong. The yuan accounted for 0.3% of the turnover in the foreign exchange market according to the BIS 2010 triennial survey (actually slightly less than in the prior 2007 survey), which is 1/8 the turnover of the Hong Kong dollar. The internationalization of the use of the yuan is largely a function thus far of converting the special administrative region into an “offshore” center.

More steps toward the internationalization of the China’s capital markets are likely. There is talk that in the coming months, China may allow foreign companies to list their shares on the Shanghai stock exchange. There may be efforts to encourage the Panda bond market (foreign companies issuing yuan bonds on the mainland). The development will take place under the guiding hand of China, for whom stability remains a guiding principle. This evolution will build institutional capacity, but a fully open capital account and full convertibility of the yuan still appears to be at least several years away. It is far too premature to speak of a challenge to the greenback by the redback (yuan), though it continues to catch the fancy of many observers.

Article courtesy of Marc Chandler